Reconsideration Of Cirrhosis In Drug Development

S2-E43.3 – Driving A Reconsideration Of Cirrhosis In Drug Development

Jörn Schattenberg joins the Surfers to discuss drug development in cirrhosis. This conversation focuses on how to drive a broader change in perspective.

Once we accept the idea that cirrhosis can make an excellent target for drug development driven using non-invasive testing, the question is take the lead in bringing the appropriate initiative forward. Stephen Harrison points out that principal investigator KOLs are the group with the most knowledge and perspective but later notes that work-life balanced for these exceptionally busy people might limit their involvement. The group considers other stakeholders until Louise Campbell asks a question toward the end of this conversation that shifts panelists’ focus from traditionally, static guidance documents to a continuously updated living document similar to what exists for Hepatitis C.

Request A Transcript of This Episode
Request Transcript

Join The Discussion…

Ask Our Panelists A Question…

Podcast Quesitonaire
Is your question directed towards one of our panelists?

If your question is answered in our next Podcast, would you like be tagged?

Join The Discussion!

Subscribe to our free emails. Receive access to our Discussion Group. Ask your questions directly to our "Surfers"